This review discusses the connection between hair follicles and dermal adipose tissue, suggesting that improving the adipogenic environment could be important for treating alopecia and enhancing hair restoration procedures, but reports no new results.
This study found that stimulating dermal papilla cells with specific adipo-osteogenic factors and growth factors helped maintain their viability and restored their hair-forming activity in vitro.
September 2022 in “Institutional Repositories DataBase (IRDB)”
Adipose-derived stem cells can be transformed into hair-forming cells using specific extracellular vesicles, offering potential for hair regeneration therapies.
5 citations
,
April 1984 in “Archives of Dermatology”
This article reviews the characteristics, causes, and types of porphyria cutanea tarda but presents no new findings, focusing instead on existing knowledge about the disorder.
A 27-year-old male with AGA and diffused thinning has been using oral Minoxidil, Finasteride, Vitamin D, B12, Iron, and Ketoconazole shampoo. Despite a hair transplant and improved blood levels, he continues to experience hair loss and suspects a possible misdiagnosis of Alopecia Areata Incognita.
The user is experiencing hair loss with possible causes including chronic telogen effluvium, diffuse alopecia areata, and androgenic alopecia. They have tried treatments like Nizoral shampoo, minoxidil, and finasteride, and are considering a biopsy for further clarity.
A 25-year-old male experienced significant hair loss due to telogen effluvium and androgenetic alopecia. He began using finasteride, minoxidil, and vitamins, seeing some regrowth but remains worried about hair density.
A 19-year-old male with no family history of androgenetic alopecia (AGA) is experiencing hair loss and considering using a topical minoxidil and finasteride mixture. Despite low vitamin D levels and normal DHT serum levels, he seeks confirmation of AGA before starting treatment.
A 20-year-old woman with androgenetic alopecia feels depressed about her hair loss, despite using topical minoxidil, spironolactone, and saw palmetto. Suggestions include trying oral minoxidil, higher doses of finasteride or dutasteride, and checking for vitamin deficiencies and heavy metal exposure.
HMI-115: Frequently Asked Questions About Hair Loss TreatmentHMI-115 is an investigational anti-prolactin-receptor antibody being trialled for androgenetic alopecia. It is not approved anywhere; its hair-loss evidence is a 16-person Phase 1b announced only by press release, plus a completed 192-man Phase 2 in China whose results are not yet published.